Bone and Mineral Metabolism in Health and Disease¶
Chapter 421 | Part 12: Endocrinology and Metabolism
KEY CLINICAL POINTS¶
- Bone is a dynamic tissue regulated by osteoblasts (bone formation) and osteoclasts (bone resorption), with osteocytes as key mechanosensors.
- Calcium homeostasis involves intestinal absorption (1,25(OH)D-dependent), renal reabsorption (PTH/FGF23 regulation), and bone remodeling.
- Phosphate metabolism is controlled by PTH, FGF23, and renal tubular reabsorption, with hypophosphatemia and hyperphosphatemia having distinct etiologies.
- Vitamin D synthesis occurs in the skin (7-dehydrocholesterol → cholecalciferol) and is activated in the liver (25(OH)D) and kidney (1,25(OH)D).
- Disorders like rickets, osteomalacia, and hypoparathyroidism are linked to vitamin D deficiency or resistance, requiring targeted treatment with calcitriol or phosphate supplements.
1. DEFINITION & OVERVIEW¶
Bone is a dynamic tissue undergoing constant remodeling. Osteoblasts synthesize bone matrix and regulate mineralization, while osteoclasts resorb bone. Osteocytes act as mechanosensors and regulators of bone remodeling. Bone serves as a reservoir for calcium, phosphorus, and other minerals, with mineralization occurring via primary and secondary phases.
Table 421-1: Causes of Hypophosphatemia¶
| Category | Causes |
|---|---|
| Reduced renal tubular phosphate reabsorption | PTH/PTHrP-dependent (e.g., hyperparathyroidism), PTH/PTHrP-independent (e.g., FGF23 excess) |
| Impaired intestinal phosphate absorption | Aluminum antacids, sevelamer, malabsorption syndromes |
| Shifts of extracellular phosphate into cells | IV glucose, insulin therapy, respiratory alkalosis |
| Accelerated net bone formation | Post-parathyroidectomy, vitamin D treatment, osteoblastic metastases |
1.1 Bone Structure and Metabolism¶
Bone matrix consists of 90–95% type I collagen and noncollagenous proteins (osteocalcin, osteopontin). Mineralization occurs via hydroxyapatite deposition, regulated by alkaline phosphatase and FGF23. Osteocytes secrete FGF23, which modulates phosphate homeostasis.
1.2 Bone Remodeling¶
Bone remodeling involves the basic multicellular unit (BMU), with osteoclasts resorbing bone and osteoblasts forming new bone. The process is regulated by mechanical stress, PTH, 1,25(OH)D, and cytokines like RANKL/OPG.
2. EPIDEMIOLOGY¶
Calcium and phosphate disorders are common in chronic kidney disease, malnutrition, and aging. Hypophosphatemia is prevalent in malnourished patients, while hyperphosphatemia is linked to renal insufficiency. Vitamin D deficiency affects ~29% of obese children and 15–30% of elderly populations.
2.1 Risk Factors¶
Risk factors include renal failure, malnutrition, excessive phosphate intake, vitamin D deficiency, and genetic disorders (e.g., X-linked hypophosphatemia).
3. ETIOLOGY & PATHOPHYSIOLOGY¶
Disorders arise from imbalances in calcium, phosphate, and vitamin D metabolism. PTH, FGF23, and vitamin D regulate mineral homeostasis. Genetic mutations (e.g., PHEX, TRPM6) cause hereditary disorders like hypophosphatemic rickets and hypomagnesemia.
Table 421-2: Intravenous Therapy for Hypophosphatemia¶
| Serum Phosphorus (mmol/L) | Rate (mmol/h) | Duration (h) | Total Administered (mmol) |
|---|---|---|---|
| <0.8 (<2.5) | 2 | 6 | 12 |
| <0.5 (<1.5) | 4 | 6 | 2,4 |
| <0.3 (<1) | 8 | 6 | 48 |
3.1 Calcium Regulation¶
Calcium absorption is 20–70% via 1,25(OH)D-dependent active transport. Renal reabsorption is regulated by PTH and 1,25(OH)D, with excess calcium excreted via urine.
3.2 Phosphate Regulation¶
Phosphate reabsorption in the proximal tubule is controlled by PTH, FGF23, and NaPi-2 co-transporters. Hypophosphatemia results from renal wasting, intestinal malabsorption, or cellular sequestration.
4. CLINICAL FEATURES¶
Symptoms include muscle weakness, tetany, seizures, and bone pain. Hypocalcemia and hypophosphatemia cause osteomalacia, while hypercalcemia leads to nephrocalcinosis. Vitamin D deficiency presents with rickets in children or osteomalacia in adults.
4.1 Hypophosphatemia¶
Acute hypophosphatemia causes neuromuscular dysfunction (weakness, seizures), while chronic cases present with osteomalacia, rickets, or myopathy.
4.2 Hyperphosphatemia¶
Associated with renal failure, hypoparathyroidism, or excessive phosphate intake. Clinical features include calcification of soft tissues, cardiac arrhythmias, and secondary hypercalcemia.
5. DIFFERENTIAL DIAGNOSIS¶
Differential diagnoses for hypocalcemia include hypoparathyroidism, vitamin D deficiency, and chronic kidney disease. Hyperphosphatemia may mimic renal failure or malignancy. Hypomagnesemia overlaps with hypokalemia and hypocalcemia.
5.1 Hypocalcemia¶
Differential diagnoses: Hypoparathyroidism, vitamin D deficiency, acute pancreatitis, or drug-induced (e.g., bisphosphonates).
6. INVESTIGATIONS & DIAGNOSIS¶
Diagnostic tests include serum calcium, phosphate, PTH, 25(OH)D, and 1,25(OH)D levels. Urine calcium and phosphate excretion, bone mineral density (DXA), and imaging (e.g., X-ray for rickets) are critical. Genetic testing identifies hereditary disorders.
Table 421-3: Causes of Hyperphosphatemia¶
| Category | Causes |
|---|---|
| Impaired renal phosphate excretion | Renal insufficiency, hypoparathyroidism, pseudohypoparathyroidism |
| Massive extracellular phosphate loads | Exogenous phosphate, tissue necrosis, rhabdomyolysis |
| Transcellular phosphate shifts | Metabolic acidosis, respiratory acidosis |
6.1 Laboratory Tests¶
Key tests: Serum calcium (total and ionized), phosphate, PTH, 25(OH)D, 1,25(OH)D, creatinine, and electrolytes. Urine calcium/creatinine ratio and FGF23 levels may be required.
7. MANAGEMENT & TREATMENT¶
Treatment depends on the underlying cause. Hypophosphatemia is corrected with oral or IV phosphate, while hyperphosphatemia requires dialysis and dietary phosphate restriction. Vitamin D deficiency is managed with ergocalciferol or cholecalciferol, with severe cases requiring calcitriol.
Table 421-4: Causes of Hypomagnesemia¶
| Category | Causes |
|---|---|
| Impaired intestinal absorption | Malabsorption, TRPM6 mutations |
| Increased intestinal losses | Vomiting, diarrhea, fistulas |
| Impaired renal reabsorption | Gitelman’s syndrome, Bartter’s syndrome |
| Rapid shifts | Refeeding syndrome, diabetic ketoacidosis |
7.1 Hypophosphatemia¶
Acute cases: IV phosphate (e.g., NaHCO3, KCl) with careful monitoring of Ca×P product. Chronic cases: Oral phosphate supplements with calcium and vitamin D.
7.2 Hyperphosphatemia¶
Dialysis for renal failure; phosphate binders (e.g., sevelamer), and correction of underlying causes (e.g., hypoparathyroidism).
8. PROGNOSIS & COMPLICATIONS¶
Chronic hypocalcemia/ hypophosphatemia leads to osteomalacia, fractures, and muscle weakness. Severe hypomagnesemia causes arrhythmias, seizures, and cardiac arrest. Untreated vitamin D deficiency results in rickets or osteomalacia, with long-term risks of bone deformities and fractures.
8.1 Complications¶
Complications include secondary hyperparathyroidism, renal stones, and cardiovascular disease. Severe hypocalcemia may cause tetany, seizures, or cardiac arrhythmias.
9. SPECIAL CONSIDERATIONS¶
In pregnancy, vitamin D deficiency increases maternal and fetal risks. Elderly patients are prone to osteoporosis and fractures. Pediatric rickets requires calcium and vitamin D supplementation. Renal failure patients need phosphate binders and dialysis.
9.1 Pregnancy¶
Pregnancy increases calcium demand; vitamin D deficiency may lead to maternal osteomalacia and fetal growth retardation.
10. KEY POINTS & CLINICAL PEARLS¶
- Bone remodeling is regulated by PTH, 1,25(OH)D, and FGF23.
- Hypophosphatemia is common in malnutrition and renal failure; hyperphosphatemia is a complication of chronic kidney disease.
- Vitamin D deficiency is a leading cause of rickets and osteomalacia; treatment requires calcium, phosphate, and vitamin D supplementation.
- Monitor Ca×P product to prevent calcification.
- Severe hypocalcemia requires IV calcium, while chronic cases benefit from oral supplementation.